Team is first in Texas to investigate convalescent plasma for prevention of COVID-19 onset and progression
A research team is the first in Texas to investigate whether plasma from COVID-19 survivors can be used in outpatient settings to prevent the onset and progression of the virus in two new clinical trials at The University of Texas Health Science Center at Houston (UTHealth).
Convalescent Plasma to Stem Coronavirus will assess whether convalescent plasma can prevent infection or severity of disease in outpatients including healthcare workers who have had a high-risk exposure to COVID-19. Convalescent Plasma to Limit SARS-CoV-2 Associated Complications will investigate whether plasma therapy can reduce hospitalization and death prior to hospitalization among adults who have tested positive for COVID-19 and have developed symptoms.
July 9, 2020